Enamel matrix derivatives in periodontal regenerative surgery modulates cytokine profiles: A randomised controlled clinical trial

Regional Committees for Medical and Health Research Ethics (REK)0 sites15 target enrollmentFebruary 22, 2016

Overview

No summary available.

Registry

who.int

Start Date

February 22, 2016

End Date

TBD

Last Updated

9 years ago

Study Type

Interventional

Sex

All

Sponsor

Regional Committees for Medical and Health Research Ethics (REK)

•1\. Aged between 25 and 75 years
•2\. Non\-smoking
•3\. No use of antibiotics over the previous 6 months prior to treatment
•4\. The presence of one pair of interproximal sites with probing pocket depth (PPD) of 6 mm or more, horizontal and/or vertical bone loss as demonstrated by the probing measurement and radiographic assessments following the initial phase of periodontal treatment
•5\. Experimental teeth must either have a vital pulp or, if subjected to root canal treatment, be asymptomatic, and without technical remarks
•6\. Prior to the start of the trial, the patients will give informed consent

•1\. Patients with a systemic condition like diabetes mellitus, cancer, HIV, disorders that compromise wound healing, chronic high dose steroid therapy, bone metabolic disease, radiation or immune\-suppressive therapy
•2\. Patients with acute infectious lesions in the area of intended therapy